Serum uromodulin is associated with the severity of clinicopathological findings in ANCA-associated glomerulonephritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Antibodies, Antineutrophil Cytoplasmic* ; Glomerulonephritis*/blood ; Glomerulonephritis*/pathology ; Glomerulonephritis*/urine ; Kidney Failure, Chronic*/blood ; Kidney Failure, Chronic*/pathology ; Kidney Failure, Chronic*/urine ; Uromodulin*/blood ; Uromodulin*/urine; Aged ; Female ; Glomerular Filtration Rate ; Humans ; Kidney/metabolism ; Kidney/pathology ; Male ; Middle Aged ; Risk Factors
    • Abstract:
      Background: Uromodulin (UMOD), also known as Tamm-Horsfall protein, is a kidney-specific protein expressed by epithelial cells lining the thick ascending limb of the loop of Henle. In the current study, we aimed to clarify the clinical significance of UMOD in ANCA-associated glomerulonephritis (AAG).
      Materials and Methods: Sixty-one biopsy-proven AAG patients were included in this study. UMOD was measured using ELISA. The relationships between serum UMOD (sUMOD) levels and various clinicopathological findings were evaluated.
      Results: AAG was classified into four categories (focal, crescentic, mixed, and sclerotic). In addition, tubulointerstitial lesions were classified as mild, moderate, and severe. The levels of sUMOD and urinary UMOD (uUMOD) were correlated with each other. A negative correlation between sUMOD levels and serum Cr levels, and positive correlation between sUMOD levels and eGFR were found. Patients in the high sUMOD group were associated with low serum Cr levels, focal classification, and mild tubulointerstitial injury compared to the low sUMOD group. Comparing the characteristics among histopathological classes, patients in the focal class had the best renal function and the highest levels of uUMOD/Cr and sUMOD. The focal class had significantly better renal survival compared with the severe histopathological classes (crescentic, mixed, and sclerotic). In univariate logistic regression analyses, prognostic factors for severe histopathological classes were low uUMOD/Cr, high serum Cr, and low sUMOD. Multivariate analyses revealed that low sUMOD predicted severe histopathological classes independent of serum Cr. The mean levels of sUMOD were significantly different between the focal class and severe histopathological classes, with a sensitivity of 70.6% and specificity of 90.0% (cut-off 143 ng/ml, AUC 0.80) by ROC curves.
      Conclusion: Low sUMOD levels were associated with severe clinicopathological findings and might be considered as a risk factor for end stage renal disease in AAG.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      Eur J Clin Invest. 2005 Apr;35(4):227-35. (PMID: 15816991)
      J Immunol. 1997 Apr 1;158(7):3449-56. (PMID: 9120306)
      Kidney Int. 2001 Mar;59(3):932-40. (PMID: 11231348)
      Am J Kidney Dis. 2003 Oct;42(4):658-76. (PMID: 14520616)
      J Am Soc Nephrol. 2010 Oct;21(10):1628-36. (PMID: 20616173)
      J Infect Dis. 1988 Dec;158(6):1379-82. (PMID: 3058823)
      Arthritis Rheum. 1994 Feb;37(2):187-92. (PMID: 8129773)
      J Rheumatol. 2013 May;40(5):674-83. (PMID: 23547217)
      Clin J Am Soc Nephrol. 2017 Jan 6;12(1):10-18. (PMID: 27797887)
      PLoS One. 2013 Aug 22;8(8):e71023. (PMID: 23990922)
      Cell Physiol Biochem. 2010;26(3):311-8. (PMID: 20798515)
      J Exp Med. 1952 Jan;95(1):71-97. (PMID: 14907962)
      J Biol Chem. 2011 Aug 26;286(34):30200-10. (PMID: 21737451)
      Science. 1987 Sep 18;237(4821):1479-84. (PMID: 3498215)
      Nat Genet. 2009 Jun;41(6):712-7. (PMID: 19430482)
      Nephrol Dial Transplant. 2012 Jun;27(6):2343-9. (PMID: 22121235)
      Kidney Int. 1993 Nov;44(5):1014-21. (PMID: 8264130)
      Biomarkers. 2017 Mar;22(2):171-177. (PMID: 27790922)
      Clin Exp Nephrol. 2013 Oct;17(5):659-662. (PMID: 23263238)
      Molecules. 2017 Jun 14;22(6):null. (PMID: 28613246)
      Nephrol Dial Transplant. 2018 Feb 1;33(2):284-295. (PMID: 28206617)
      Wien Klin Wochenschr. 2005 May;117(9-10):316-22. (PMID: 15989109)
      Science. 1987 Apr 3;236(4797):83-8. (PMID: 3453112)
      Clin Chem Lab Med. 2014 Dec;52(12):1755-61. (PMID: 24933630)
      Am J Nephrol. 2018;47(4):275-282. (PMID: 29698955)
      Immunol Cell Biol. 2002 Dec;80(6):558-66. (PMID: 12406390)
      Science. 1985 Aug 2;229(4712):479-81. (PMID: 2409603)
      Transpl Immunol. 2008 Jan;18(3):237-45. (PMID: 18047931)
      Kidney Int. 2015 Nov;88(5):944-6. (PMID: 26579681)
      Clin Rheumatol. 2018 Apr;37(4):1065-1074. (PMID: 29520673)
      Medicine (Baltimore). 2016 Mar;95(10):e3011. (PMID: 26962815)
      J Biol Chem. 2011 Jan 21;286(3):2224-35. (PMID: 21081491)
      Proc Soc Exp Biol Med. 1950 May;74(1):106-8. (PMID: 15430405)
      Diabetes Care. 2019 Feb;42(2):297-302. (PMID: 30482755)
    • Accession Number:
      0 (Antibodies, Antineutrophil Cytoplasmic)
      0 (UMOD protein, human)
      0 (Uromodulin)
    • Publication Date:
      Date Created: 20191115 Date Completed: 20200317 Latest Revision: 20200317
    • Publication Date:
      20240829
    • Accession Number:
      PMC6855443
    • Accession Number:
      10.1371/journal.pone.0224690
    • Accession Number:
      31725735